Olaparib-Induced Anemia and Radiation Therapy

Introduction to Olaparib-Associated Anemia Risk

• Anemia is the most common dose-limiting toxicity of olaparib, occurring in 9-46% of patients depending on severity, and while radiation therapy to skeletal sites can independently cause hematologic toxicity, there is no specific evidence addressing the combined risk of olaparib and radiation therapy together 1, 2

Radiation Therapy and Hematologic Toxicity

• Radiation therapy to the cranium and/or spine causes grade 3-4 hematologic side effects in approximately one-third of patients 2
• Skeletal radiation is specifically associated with hematologic toxicity due to bone marrow involvement 2

Mandatory Monitoring and Management

• The National Comprehensive Cancer Network (NCCN) guidelines explicitly require careful monitoring of complete blood counts during olaparib therapy 1, 3, 5
• The NCCN guidelines also require type and screen availability 1, 3
• Transfusion support readiness is necessary, according to the NCCN guidelines 1, 3, 5
• Dose reductions for severe anemia or intolerance are recommended by the NCCN guidelines 1, 3, 5

Clinical Approach When Combining Olaparib with Radiation

• Patients receiving skeletal radiation should be considered at substantially elevated risk when also receiving olaparib 2
• Intensify CBC monitoring to at least every 2 weeks when combining therapies, particularly during and immediately after radiation 2